K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, ERBB-2 and ERBB-3 in resected pancreatic ductal adenocarcinoma

International Journal of Cancer

Volumn 89, Issue 6, 2000, Pages 469-474

  Kawesha, Anthony ^a   Ghaneh, Paula ^a   Andrén Sandberg, Åke ^b   Ögraed, Dagfinn ^b   Skar, Robert ^b   Dawiskiba, Sigmund ^c   Evans, James D ^a   Campbell, Fiona ^d   Lemoine, Nicholas ^e   Neoptolemos, John P ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c LUND UNIVERSITY   (Sweden)

^d ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^e HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; PROTEIN P16; PROTEIN P21; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CODON; DISEASE MARKER; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; MALE; ONCOGENE K RAS; PANCREAS CARCINOMA; PANCREAS RESECTION; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; CARCINOMA, PANCREATIC DUCTAL; CARRIER PROTEINS; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA MUTATIONAL ANALYSIS; FEMALE; FOLLOW-UP STUDIES; GENES, ERBB; GENES, ERBB-2; GENES, RAS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTATION; PANCREATIC NEOPLASMS; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034693635     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(20001120)89:6<469::AID-IJC1>3.0.CO;2-L     Document Type: Article

References (46)

1. Prognostic factors for survival after pancreatic duodenectomy for patients with carcinoma of the pancreatic head region
2. Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer
3. The incidence and treatment and survival in 13,560 patients with pancreatic cancer: An epidemiological study in the West Midlands
4. Frequent somatic mutations and homozygous deletions of the p16 (mts1) gene in pancreatic adenocarcinoma
5. Analysis of p53, p21(WAFI), and TGF-β1 in human ductal adenocarcinoma of the pancreas
6. Molecular metastases in stage I pancreatic cancer: Improved survival with adjuvant chemoradiation
7. The clinical significance of p21(WAFI)/CIP1 and p53 expression in pancreatic adenocarcinoma
8. Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma
9. K-ras topographic genotyping of pancreatic adenocarcinoma
10. Genotypic classification of colorectal adenocarcinoma - Biologic behavior correlates with k-ras-2 mutation type
11. Tumor size is the primary prognosticator for pancreatic cancer after regional pancreatectomy
12. Enhanced erbB-3 expression in human pancreatic cancer correlates with tumour progression
13. Prognostic indicators for survival after resection of pancreatic adenocarcinoma
14. Genetic alterations of cyclins, cyclin dependent kinases and cdk inhibitors in human cancer
15. The c-erbB-2 protooncogene m human pancreatic cancer
16. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant enriched polymerase chain reaction analysis and allele specific oligonucleotide hybridisation
17. Participation of the p53 protein in the cellular response to DNA damage
18. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increase in the levels of epidermal growth factor and transforming growth factor alpha
19. p53 mutations in human cancers
20. Overexpression of her2/neu oncogene in pancreatic cancer correlates with shortened survival
21. Ki-ras oncogene activation in preinvasive pancreatic cancer
22. The c-erbB-3 gene in human pancreatic cancer
23. Prognostic significance of Ki-67 antigen and p53 protein expression in pancreatic duct carcinoma: A study of the monoclonal antibodies MIB-1 and DO7 in formalin-fixed paraffin embedded tumour material
24. Prognostic value of immunohistochemical expression of p53 m patients with pancreatic cancer
25. Aberrant p16 (INK4) expression related to clinical stage and prognosis in patients with pancreatic cancer
26. Frequent codeletion of p16/MTS1 and p15/MTS2 and genetic alterations in p16/MTS1 in pancreatic tumours
27. Adjuvant radiotherapy and follow-on chemotherapy in patients with pancreatic cancer. Results of the UK pancreatic cancer study group (UKPACA-1)
28. Progress report: A randomised multicentre European study comparing adjuvant radiotherapy, six months chemotherapy and combination therapy versus no adjuvant treatment in resectable pancreatic cancer
29. Low mortality following resection for pancreatic and periampullary tumours in 1026 patients: UK survey of specialist pancreatic units
30. p53 expression affects the efficacy of adjuvant chemotherapy after resection of invasive ductal carcinoma of the pancreas
31. Comparative significance of p53 and WAF/1-p21 expression on the efficacy of adjuvant chemotherapy for resectable invasive ductal carcinoma of the pancreas
32. Tumour suppressive pathways in pancreatic carcinoma
33. Molecular pathology of primary and metastatic ductal pancreatic lesions. Analyses of mutations and expression of the p53, mdm-2 and p2I/WAF-1 genes in sporadic and familial lesions
34. Pancreatic cancer: A report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995 using the National Cancer Database
35. A new regulatory motif in cell cycle control causing specific inhibition of cyclinD/cdk4
36. K-ras codon 12 mutations occur very frequently in pancreatic adenocarcinomas
37. A detailed analysis of K-ras point mutations in relation to tumour progression and survival in colorectal cancer patients
38. Detection and identification of Ki-ras exon 1 mutations by minigel single strand conformation polymorphism
39. Pancreatic cancer treatment in the United States veteran from 1987-1991 - Effect of tumour stage on survival
40. p53, Ki-ras and DNA ploidy in human pancreatic ductal adenocarcinomas
41. p21 is a universal inhibitor of cyclin kinases
42. p53 expression in human pancreatic cancer correlates with enhanced biological aggressiveness
43. Immunohistochemical analysis of p53 expression in human pancreatic carcinomas